Matheus Caetano Epifane de Assunção

Mr. Matheus Caetano Epifane de Assunção

Federal University of Para, Belém, Pará, Brazil
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Heliyon
Verified
Journal Article
Open access
Ricardo Cunha de OliveiraRicardo Cunha de Oliveira
Ricardo Cunha de Oliveira
FSFelipe Gouvea de Souza
Felipe Gouvea de Souza
ABAna Gabrielle Bispo
Ana Gabrielle Bispo
Matheus Caetano Epifane de AssunçãoMatheus Caetano Epifane de Assunção
Matheus Caetano Epifane de Assunção
GCGiovanna Cavalcante
Giovanna Cavalcante
Brain cancer is considered one of the most aggressive and lethal types of cancer, including primary tumors, being subdivided into milder forms such as low-grade gliomas and glioblastoma, considered the most aggressive form with higher invasion. Among the hallmarks of glioblastoma, the deregulation of mitochondrial metabolism has not yet been fully elucidated. Therefore, the search for mitochondrial biomarkers that can be used as indicators of the progression of this type of cancer is necessary. The aim of this study was to investigate the difference in gene expression between astrocytoma-type gliomas and glioblastomas, and how genes involved in mitochondrial metabolism can influence the proliferative cascade and be associated with tumor invasion. From the differential analysis of glioblastoma expression when compared to the milder form, 11 differentially expressed genes (DEGs) were found in our study, six of which were upregulated (ATP5MGL, C15orf48, MCUB, TERT, AGXT and CYP27B1) and four downregulated (SLC2A4, GK2, SLC25A48, ETNPPL and HMGCS2). To validate the findings, we used other independent bulk RNA-seq datasets and evaluated the number of normalized counts of the DEGs founded. Among these genes, we highlight that none of them had been reported in glioblastoma until this research, and we suggest these genes as possible biomarkers to be further explored, since they are associated with essential pathways for the tumor, such as glucose metabolization, gluconeogenesis, calcium and vitamin D metabolism, tumor progression and activation of the invasion cascade.

Verified
Journal Article
Open access
PDF file
LLLuciana P. C. Leitão
Luciana P. C. Leitão
DCDarlen Carvalho
Darlen Carvalho
JRJuliana Rodrigues
Juliana Rodrigues
MARIANNE RODRIGUES FERNANDESMARIANNE RODRIGUES FERNANDES
MARIANNE RODRIGUES FERNANDES
AWAlayde V. Wanderley
Alayde V. Wanderley
NSNey Santos
Ney Santos
A number of genomic variants related to native American ancestry may be associated with an increased risk of developing Acute Lymphoblastic Leukemia (ALL), which means that Latin American and hispanic populations from the New World may be relatively susceptible to this disease. However, there has not yet been any comprehensive investigation of the variants associated with susceptibility to ALL in traditional Amerindian populations from Brazilian Amazonia. We investigated the exomes of the 18 principal genes associated with susceptibility to ALL in samples of 64 Amerindians from this region, including cancer-free individuals and patients with ALL. We compared the findings with the data on populations representing five continents available in the 1000 Genomes database. The variation in the allele frequencies found between the different groups was evaluated using Fisher’s exact test. The analyses of the exomes of the Brazilian Amerindians identified 125 variants, seven of which were new. The comparison of the allele frequencies between the two Amerindian groups analyzed in the present study (ALL patients vs. cancer-free individuals) identified six variants (rs11515, rs2765997, rs1053454, rs8068981, rs3764342, and rs2304465) that may be associated with susceptibility to ALL. These findings contribute to the identification of genetic variants that represent a potential risk for ALL in Amazonian Amerindian populations and might favor precision oncology measures.

20 February 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
GBGustavo Barra-Matos
Gustavo Barra-Matos
FSFelipe Gouvea de Souza
Felipe Gouvea de Souza
CSCaio Santos Silva
Caio Santos Silva
Matheus Caetano Epifane de AssunçãoMatheus Caetano Epifane de Assunção
Matheus Caetano Epifane de Assunção
MSMarcella Vitória Belém Souza
Marcella Vitória Belém Souza
Gilderlanio AraújoGilderlanio Araújo
Gilderlanio Araújo
Mitochondrial DNA (mtDNA) alterations are increasingly associated with Parkinson's disease (PD), particularly due to their role in oxidative stress. However, the contribution of mtDNA insertions and deletions (INDELs) to PD remains poorly understood, particularly in genetically admixed populations such as Brazilians. To explore this, we sequenced the complete mtDNA from blood samples of 179 admixed individuals from the Brazilian Amazon (104 people with PD and 75 controls). Data processing included FastQC, MultiQC, FastP, BWA, and mtDNA-Server 2. We identified a significantly higher burden of mtDNA INDELs in PD compared with controls in Complex I genes (OR = 9.23; 95% CI: 2.22-63.55; FDR = 0.044). Differences in heteroplasmy levels were also observed in the ATP6, ND4, and ND5 genes. Importantly, we discovered seven new PD-associated INDELs (m.13763_13763delinsCCA, m.13885_13885delinsCTG, m.13888_13890delinsT, m.13767_13769delinsC, m.13810_13812delinsG, m.13813_13813delinsGCA, and m.13764_13764delinsCAT) that are particularly more frequent among individuals harboring uniparental lineages of Native American origin. Our findings report novel mtDNA INDELs, particularly in Complex I, which may contribute to PD susceptibility and highlight the importance of investigating mitochondrial genomic variation in underrepresented populations. These associations should be interpreted as preliminary, and further longitudinal studies with independent cohorts are required to confirm these observations.

19 February 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
ABAna Gabrielle Bispo
Ana Gabrielle Bispo
FSFelipe Gouvêa de Souza
Felipe Gouvêa de Souza
Matheus Caetano Epifane de AssunçãoMatheus Caetano Epifane de Assunção
Matheus Caetano Epifane de Assunção
CSCamille Sena-Dos-Santos
Camille Sena-Dos-Santos
GBGustavo Barra-Matos
Gustavo Barra-Matos
GCGiovanna Cavalcante
Giovanna Cavalcante
Significant advances have been made in elucidating the pathophysiological mechanisms of Parkinson's disease (PD). Levodopa remains the main therapeutic option - although it presents heterogeneous clinical benefits among patients. Mutations related to levodopa metabolic pathways have been investigated, but not for mtDNA. Since levodopa metabolism is highly dependent on ionic gradients, endocytosis, and vesicular transport - all ATP-dependent processes - the normal function of OXPHOS is essential not only for adequate levodopa metabolism but also for its therapeutic efficacy. This study aimed to analyze levodopa short duration responsiveness profiles considering the mitochondrial genomic component in Brazilian admixed populations. A total of 49 patients with PD underwent a levodopa challenge test (LCT), followed by whole mitochondrial genome sequencing, pathogenicity prediction of identified variants, and in silico structural analyses. Variants most frequently affected ND4, ND5, and ND6 subunits in both groups (responsive and non-responsive). Among them, the responsive group presented variants in MT-ND4 (m.12018C > G - T420S) and ND5 (m.13130C > A - P265H) as those with the most significant structural impact, suggesting a loss of the native conformation and alterations in protein efficiency. Additionally, five unique variants were detected only among non-responsive patients, two of which were absent from the dbSNP and ClinVar databases, which indicates the possibility that they are novel variants and potentially population-specific. We provide molecular evidence suggesting that variants in mitochondrial ND4, ND5, and ND6 subunits, in addition to mitochondrial ancestry, may contribute to distinct levodopa short duration response in PD patients.

16 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
GBGustavo Barra-Matos
Gustavo Barra-Matos
Matheus Caetano Epifane de AssunçãoMatheus Caetano Epifane de Assunção
Matheus Caetano Epifane de Assunção
MBMarcella Belem-Souza
Marcella Belem-Souza
Gilderlanio AraújoGilderlanio Araújo
Gilderlanio Araújo
CSCaio Silva
Caio Silva
Gilderlanio AraújoGilderlanio Araújo
Gilderlanio Araújo
Mitochondrial single-nucleotide variants (mtSNVs) can dysregulate cellular bioenergetics and have been increasingly implicated in susceptibility to Parkinson's disease (PD). These variants may impair oxidative metabolism and respiratory chain efficiency, thus contributing to neuronal dysfunction and degeneration. In peripheral blood, mtSNVs may also reflect systemic immunometabolic alterations associated with PD; however, this aspect remains poorly explored, particularly in admixed populations with significant indigenous ancestry. In this study, we analyzed the complete mtDNA of peripheral blood samples from 179 admixed individuals (104 with PD and 75 controls) from the Brazilian Amazon. Associations between mtSNVs and PD were assessed using adjusted logistic regression models, and functional annotation was performed using the Variant Effect Predictor. Furthermore, we proposed and calculated a heteroplasmy-weighted mitochondrial polygenic risk score (mtPRS). We observed a higher mtSNV burden in PD patients, predominantly in RNR2 gene and genes of Complexes I and IV. In total, 536 unique mitochondrial SNVs were identified (214 exclusive to PD, 321 shared between PD and controls, and one exclusive to controls). Four mitochondrial SNVs were associated with PD, including three novel variants (COX1: m.6630G>A, COX2: m.7613C>T, and RNR2: m.1996C>T) and one previously reported variant (ND4: m.12112C>T). Notably, the mitochondrial polygenic risk score (mtPRS) showed a strong association with increased PD risk (OR = 3.64; FDR = 1.12 x 10e-6). Taken together, these results suggest that mtSNVs may contribute to PD susceptibility in admixed Amazonian population, highlighting the relevance of mitochondrial genetic architecture in PD and emphasizing the importance of including underrepresented populations in genomic research.

1 January 2024 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
Ricardo Cunha de OliveiraRicardo Cunha de Oliveira
Ricardo Cunha de Oliveira
FSFelipe Gouvea de Souza
Felipe Gouvea de Souza
ABAna Gabrielle Bispo
Ana Gabrielle Bispo
Matheus Caetano Epifane de AssunçãoMatheus Caetano Epifane de Assunção
Matheus Caetano Epifane de Assunção
GCGiovanna Cavalcante
Giovanna Cavalcante
Brain cancer is considered one of the most aggressive and lethal types of cancer, including primary tumors, subdivided into milder forms such as low-grade gliomas and glioblastoma, considered the most aggressive form with metastasis. Among the hallmarks of glioblastoma, the deregulation of mitochondrial metabolism has not yet been fully elucidated. Therefore, the search for mitochondrial biomarkers that can be used as indicators of the progression of this type of cancer is necessary. The aim of this study was to investigate the difference in gene expression between astrocytoma-type gliomas and glioblastomas, and how genes involved in mitochondrial metabolism can influence the proliferative cascade and be associated with tumor invasion. From the differential analysis of glioblastoma expression when compared to the milder form, 11 differentially expressed genes were found in our study, six of which were upregulated (ATP5MGL, C15orf48, MCUB, TERT, AGXT and CYP27B1) and four downregulated (SLC2A4, GK2, SLC25A48, ETNPPL and HMGCS2). Among these genes, we highlight that none of them had been reported in glioblastoma until this research, and we suggest these genes as possible biomarkers, since they are associated with essential pathways for the tumor, such as glucose metabolization, gluconeogenesis, calcium and vitamin D metabolism, tumor progression and activation of the metastatic cascade.